Guidance on the Implementation of the Ministerial Ordinance on the Good Laboratory Practice for Nonclinical Safety Studies of Drugs as Revised by the Ministerial Ordinance for the Partial Revision of the Ministerial Ordinance on the Good Laboratory Practice for Nonclinical Safety Studies of Drugs
2008-06-13
PFSB Notification No. 0613007
法律行政法规
日本
现行有效
/
日本医疗器械审评审批机构(PMDA)
最新政策法规资讯
-
摩熵医药2026-06-17
-
摩熵医药2026-06-09
-
赛柏蓝2026-06-01
-
深蓝观2026-05-22
-
赛柏蓝2026-04-24
-
摩熵医械2026-01-28
-
摩熵医械2026-01-13
-
摩熵医械2025-12-19
-
赛柏蓝2025-12-12
-
摩熵医械2025-11-28
热门政策标签
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-08-31
-
2026-08-31
-
摩熵咨询 35 47
-
摩熵咨询 28 48
-
颁布机构：国家市场监督管理总局 2026-08-10
-
颁布机构：国家市场监督管理总局 2026-05-29
最新法律行政法规
-
中华人民共和国药品管理法实施条例
2026-01-27
-
生物医学新技术临床研究和临床转化应用管理条例
2025-10-10
-
国务院关于加强监管防范风险推动保险业高质量发展的若干意见
2024-09-11
-
推动大规模设备更新和消费品以旧换新行动方案
2024-03-18
-
人体器官捐献和移植条例
2023-12-14
-
支持北京深化国家服务业扩大开放综合示范区建设工作方案
2023-11-23
-
国务院关于推进普惠金融高质量发展的实施意见
2023-10-11
-
社会保险经办条例
2023-09-01
-
国务院关于做好自由贸易试验区第七批改革试点经验复制推广工作的通知
2023-07-10
-
Points to Consider for Informed Consent Using Electromagnetic Means in Clinical Trials and Post-marketing Clinical Trials
2023-03-30
-
数字中国建设整体布局规划
2023-02-27
-
中共中央 国务院关于做好2023年全面推进乡村振兴重点工作的意见
2023-02-13
-
中共中央 国务院印发《质量强国建设纲要》
2023-02-07
-
加强当前农村地区新型冠状病毒感染疫情防控工作方案
2022-12-31
-
关于进一步优化落实新冠肺炎疫情防控措施的通知
2022-12-07
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-08-31
-
2026-08-31
-
2026-08-31
-
摩熵咨询 20 8
-
摩熵咨询 34 38
-
摩熵咨询 20 5
-
颁布机构：四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构：国家医保局 2026-07-31
-
颁布机构：国家药品审评中心（CDE） 2026-07-24
同部门最新法律行政法规
-
Points to Consider for Informed Consent Using Electromagnetic Means in Clinical Trials and Post-marketing Clinical Trials
2023-03-30
-
Dr. Yasuhiro Fujiwara, Chief Executive of PMDA, re-elected Vice Chair of the International Coalition of Medicines Regulatory Authorities (ICMRA) (News Release)
2022-07-19
-
Procedure for Remote Inspection as a Part of Compliance Inspection on Drugs and Regenerative Medical Products
2022-05-25
-
Amendment to “Basic Principles on Global Clinical Trials (Reference Cases)”
2021-12-10
-
English Translations of Guidelines for Bioequivalence Studies of Generic Products
2021-09-14
-
Basic Concept on Bioequivalence Evaluation for Addition of Formulations with Different Dosage Forms in Ethical Kampo Formulations
2021-07-19
-
Basic principles on Utilization of Registry for Applications
2021-03-23
-
Points to Consider for Ensuring the Reliability in Utilization of Registry Data for Applications
2021-03-23
-
Guidelines for Analysis Reports Involving Physiologically based Pharmacokinetic Models
2020-12-21
-
Procedure for Remote Inspection as a part of compliance inspection on drugs and regenerative medical products
2020-11-16
-
On Release of Questions and Answers (Q&As) regarding the Guideline for Clinical Evaluation of Oral Hypoglycemic Agents
2020-07-09
-
Considerations for the Clinical Evaluation of Drugs in Pediatric Patients (10 or 12 Years of Age and Older) Who Can be Evaluated Together with Adults
2020-06-30
-
Guideline for Exposure-Response Analysis of Drugs
2020-06-08
-
Guideline for preclinical safety assessment of oligonucleotide therapeutics
2020-03-30
-
Guideline on Ensuring the Quality and Safety of Gene Therapy Products
2019-07-09
同地域最新法律行政法规
-
Points to Consider for Informed Consent Using Electromagnetic Means in Clinical Trials and Post-marketing Clinical Trials
2023-03-30
-
Dr. Yasuhiro Fujiwara, Chief Executive of PMDA, re-elected Vice Chair of the International Coalition of Medicines Regulatory Authorities (ICMRA) (News Release)
2022-07-19
-
Procedure for Remote Inspection as a Part of Compliance Inspection on Drugs and Regenerative Medical Products
2022-05-25
-
Amendment to “Basic Principles on Global Clinical Trials (Reference Cases)”
2021-12-10
-
English Translations of Guidelines for Bioequivalence Studies of Generic Products
2021-09-14
-
Basic Concept on Bioequivalence Evaluation for Addition of Formulations with Different Dosage Forms in Ethical Kampo Formulations
2021-07-19
-
Basic principles on Utilization of Registry for Applications
2021-03-23
-
Points to Consider for Ensuring the Reliability in Utilization of Registry Data for Applications
2021-03-23
-
Guidelines for Analysis Reports Involving Physiologically based Pharmacokinetic Models
2020-12-21
-
Procedure for Remote Inspection as a part of compliance inspection on drugs and regenerative medical products
2020-11-16
-
On Release of Questions and Answers (Q&As) regarding the Guideline for Clinical Evaluation of Oral Hypoglycemic Agents
2020-07-09
-
Considerations for the Clinical Evaluation of Drugs in Pediatric Patients (10 or 12 Years of Age and Older) Who Can be Evaluated Together with Adults
2020-06-30
-
Guideline for Exposure-Response Analysis of Drugs
2020-06-08
-
Guideline for preclinical safety assessment of oligonucleotide therapeutics
2020-03-30
-
Guideline on Ensuring the Quality and Safety of Gene Therapy Products
2019-07-09